CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
We are very excited to launch our new website! Please take a few moments to click around and explore...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...